Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells.
Malignant tumor cell invasion is determinant for metastasis to occur. E2 and C5 colon carcinoma cells that were derived from the parental Lovo line and that differ experimentally in spontaneous metastatic ability have been monitored for gene expression by cDNA arrays. Among genes found differentially expressed, the CD63 tetraspanin, not previously recognized in colon cancer progression, and the alpha3 integrin chain were both up-regulated in low metastatic E2 cells and were analyzed for their functional role using adhesion, migration, and invasion assays. Cell surface expression of CD63 and alpha3 integrin was about 2-fold higher in E2 than in C5 cells and confocal microscopy showed that CD63 and alpha3 integrin colocalized evenly on C5 cells whereas they concentrated at elongated tips of the low-metastatic more substrate-adhesive E2 cells. Antibody-interference experiments identified laminin-5 (LN-5) as a ligand interacting with the alpha3beta1/CD63 complex. Substrate-immobilized anti-CD63 antibodies enhanced tumor cell migration and invasion and induced prominent cell surface protrusions that were repressed by the PI3-kinase LY294002 inhibitor. Our results suggest that changes in the expression of surface CD63 and alpha3beta1 integrin interacting with LN-5 could affect migratory signals and the progression of the metastatic disease.
Sordat
Isabelle
I
Experimental and Molecular Pathology Unit, Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland.
Decraene
Charles
C
Silvestre
Timothée
T
Petermann
Olivier
O
Auffray
Charles
C
Piétu
Geneviève
G
Sordat
Bernard
B
D019138:Antibodies, Blocking / Q000494:pharmacology; D015703:Antigens, CD / Q000235:genetics* / Q000378:metabolism; D002277:Carcinoma / Q000235:genetics* / Q000378:metabolism* / Q000556:secondary; D002448:Cell Adhesion / Q000187:drug effects; D015815:Cell Adhesion Molecules / Q000276:immunology / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D002867:Chromones / Q000494:pharmacology; D002999:Clone Cells; D003110:Colonic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018076:DNA, Complementary / Q000032:analysis*; D004273:DNA, Neoplasm / Q000032:analysis; D004791:Enzyme Inhibitors / Q000494:pharmacology; D020869:Gene Expression Profiling; D006801:Humans; D039201:Integrin alpha3beta1 / Q000235:genetics* / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D010980:Platelet Membrane Glycoproteins / Q000235:genetics* / Q000378:metabolism; D012334:RNA, Neoplasm / Q000032:analysis; D060149:Tetraspanin 30; D014407:Tumor Cells, Cultured; D015854:Up-Regulation; D014945:Wound Healing / Q000187:drug effects; D000097794:Kalinin
D019138:Antibodies, Blocking; D015703:Antigens, CD; D015815:Cell Adhesion Molecules; D002867:Chromones; D018076:DNA, Complementary; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D039201:Integrin alpha3beta1; D009025:Morpholines; D010980:Platelet Membrane Glycoproteins; D012334:RNA, Neoplasm; D060149:Tetraspanin 30; D000097794:Kalinin; C554586:CD63 protein, human; C085911:2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one